Compugen Ltd. (USA)  

(Public, NASDAQ:CGEN)   Watch this stock  
Find more results for CGEN
6.83
+0.01 (0.15%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.76 - 6.98
52 week 4.32 - 7.98
Open 6.81
Vol / Avg. 39,038.00/101,973.00
Mkt cap 348.45M
P/E     -
Div/yield     -
EPS -0.45
Shares 50.57M
Beta 0.94
Inst. own 13%
Aug 2, 2016
Q2 2016 Compugen Ltd Earnings Release (Estimated) - 2:45AM EDT - Add to calendar
Jul 21, 2016
Compugen Ltd Annual Shareholders Meeting (Estimated) - 3:00AM EDT - Add to calendar
May 10, 2016
Q1 2016 Compugen Ltd Earnings Call
May 10, 2016
Q1 2016 Compugen Ltd Earnings Release
Apr 13, 2016
Compugen Ltd Extraordinary Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -9248.39% -217.34%
Operating margin -9538.71% -225.48%
EBITD margin - -213.56%
Return on average assets -36.18% -18.82%
Return on average equity -39.93% -20.57%
Employees 93 -
CDP Score - -

Address

72 Pinchas Rosen Street
TEL AVIV-YAFO, 6951294
Israel
+972-3-7658585 (Phone)
+972-3-7658555 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology. The Company's therapeutic proteins for immunology include CGEN-15001T, CGEN-15022, CGEN-15029, CGEN-15049 and CGEN-15092, which are based on B7/CD28-like immune checkpoint candidates. It offers various infrastructure platforms, which include LEADS, MED and LINKS, which integrates its scientific understandings and predictive models. It offers various target discovery platforms, which include Antibody-Drug Conjugate Cancer Therapy Discovery Platform, Other Discovery Approaches for Immunomodulatory Proteins and Biomarker Discovery Approaches.

Officers and directors

Martin S. Gerstel Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Anat Cohen-Dayag Ph.D. President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Ari Krashin Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Zurit Levine Ph.D. Vice President - Research and Discovery
Age: 47
Bio & Compensation  - Reuters
John Hunter Vice President - Antibody Research & Development
Age: 52
Bio & Compensation  - Reuters
Dov Hershberg Director
Age: 75
Bio & Compensation  - Reuters
Yair Aharonowitz Ph.D. Independent External Director
Age: 74
Bio & Compensation  - Reuters
Ruth Arnon Independent Director
Age: 80
Bio & Compensation  - Reuters
Arie Ovadia Independent External Director
Age: 67
Bio & Compensation  - Reuters
Joshua Shemer M.D. Independent External Director
Bio & Compensation  - Reuters